108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
阿帕替尼单药治疗复发性卵巢癌并获长期无进展生存 1 例：病例报道及文献复习
Authors Zhang D, Huang J, Sun Y, Guo Q
Received 20 December 2018
Accepted for publication 27 March 2019
Published 15 May 2019 Volume 2019:12 Pages 3635—3644
DOI https://doi.org/10.2147/OTT.S198946
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Rachel Predeepa
Peer reviewer comments 2
Editor who approved publication: Dr Leo Jen-Liang Su
摘要：卵巢癌是最致命的妇科恶性肿瘤，对女性健康构成极大威胁。抗血管生成治疗可为卵巢癌患者带来临床获益。阿帕替尼是一种口服小分子血管内皮生长因子受体-2 抑制剂，在多种实体瘤中展示出显著的治疗效果。我们报告了一例晚期卵巢癌患者，在多线治疗方案失败后，接受阿帕替尼 250mg/d 治疗，并通过文献复习进行讨论。该患者无进展生存期长达 24 个月，且生活质量良好。阿帕替尼单药治疗可能为晚期卵巢癌提供了一种新的治疗方案，但仍需进一步观察和探索。
关键词：卵巢癌，阿帕替尼单药治疗，抗血管生成治疗，血管内皮生长因子受体
